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Abstract: 
The purine ATP has a prominent regulatory role in CNS function and pathology due to its 
actions on glial cells - microglia, astrocytes and oligodendrocytes. ATP serves as an 
apparently ubiquitous ‘gliotransmitter’ that is released by astrocytes and other cells to 
activate purine receptors on neighbouring cells. In pathology, the release of ATP mediates 
both tissue damage and repair by its direct effects on glial cell integrity and survival. The 
actions of ATP on glia are mediated via a wide range of receptors, broadly divided into 
ionotropic P2X and metabotropic (G-protein coupled receptors (GPCR) P2Y receptors, of 
which there are multiple subtypes (P2X1-P2X7 and P2Y1-P2Y14). ATP-mediated interactions 
between astrocytes and microglia are at the centre of immune responses in the CNS, with 
prominent roles for the P2X4, P2X7, P2Y1, P2Y6 and P2Y12 receptor subtypes. In 
oligodendrocytes, P2X7 and P2Y1 receptor subtypes have a bipartite function in respectively 
mediating oligodendrocyte destruction and protection. Purine receptors mediate glial 
pathology, with prominent roles in ischemia, neuroinflammation, Multiple Scelerosis, 
neuropathic pain and traumatic injury. Notably, glial ATP signalling may be altered with 
ageing and is implicated in impaired myelination and immunity in Alzheimer’s disease. 
Hence, glial purine receptors provide potential therapeutic targets in multiple 
neuropathologies, but the ‘Jeckyll and Hyde’ nature of purine signalling underscores the 
importance of further research and a comprehensive understanding of the roles of the 
different purine receptors in mediating tissue damage and repair. 
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BACKGROUND 
The main types of glia in the central nervous system (CNS) are astrocytes, 
oligodendrocytes and microglia, each of which are specialised to perform specific functions 
to enable CNS function and are integral to all neuropathologies (1). Astrocytes are 
multifunctional cells with essential neuron supporting functions, including homeostasis, 
metabolic support, neurovascular coupling and forming the neuroprotective scar following 
injury. Furthermore, astrocytes encompass synapses and play a critical role in 
neurotransmitter uptake and are implicated in synaptic transmission as part of the tripartite 
synapse (2). Oligodendrocytes are responsible for myelination, which is essential for rapid 
axonal communication and higher cognitive function (3, 4). Microglia have a macrophage 
function and provide the innate immunity in the CNS (5). A universal property of glial cells is 
their responsiveness to ATP through their expression of multiple purine receptors (6). 
Purinoceptors mediate the characteristic responses of glia to CNS insults – astrocyte 
reactivity, microglial activation and oligodendrocyte/myelin loss. Hence, glial purinoceptors 
are potential therapeutic targets in multiple CNS disease states.  
 
GLIAL PURINE RECEPTORS 
Purine receptors are broadly divided into adenosine (P1) and ATP (P2) receptors, and 
there is evidence for expression of both groups in different glial cells (6).  P2 receptors (P2R) 
are further divided into ionotropic P2XR and G-protein coupled metabotropic P2YR, which 
can be distinguished by a range of agonists and antagonists (7). There are seven P2XR 
subunits (P2X1-7), which assemble as trimers to form homomeric and heteromeric receptors 
with a diverse range of properties (8). P2XR are cationic ligand-gated channels permeable to 
Na+, K+ and Ca2+, and most are activated at low concentrations of ATP, with EC50 of 1–10 M, 
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whereas P2X7R are activated at high concentrations of ATP, in the 0.1-1 mM range, and are 
capable of pore formation, resulting in sustained influx of Ca2+ (7). There are eight subtypes 
of P2YR, which exhibit different preferences for ATP/ADP (P2Y1, P2Y11, P2Y12, and P2Y13), 
ATP/UTP (P2Y2), UTP (P2Y4), UDP (P2Y6) or UDP-glucose and other nucleotide sugars (P2Y14) 
(7). P2YR may assemble as homodimers or heterodimers with other P2YRs or with other G-
protein coupled receptors, which increases their diversity further (9). 
 
Two key features of glial P2R is the predominant role for P2Y1R in glial calcium 
signalling and for P2X7R in glial pathology (6, 10). In astrocytes, activation of P2Y1R results in 
an increase in cytosolic Ca2+, often referred to as glial ‘calcium signalling’, which is 
propagated between cells by astroglial release of ATP to activate receptors on neighbouring 
cells in a ‘spillover’ or volume transmission manner (11, 12). Astroglial ATP release in 
physiological signalling may be primarily vesicular and through connexin-43 (Cx43) 
hemichannels, although they can also release ATP through pore-forming P2X7R, pannexin-1 
hemichannels, and volume-regulated anion channels, but the relative importance of the 
different mechanisms in physiological and pathological signalling is unclear (13-16). 
Microglia may also release ATP via Cx43 and vesicles (17, 18), and during ischemia 
oligodendrocytes can release ATP through pannexin hemichannels (19). Nonetheless, ATP 
release under physiological conditions may be principally from astrocytes and appears to act 
on astrocytes and oligodendrocytes predominantly via P2Y1R, which cause a rise in [Ca
2+]i 
through IP3-dependent release of Ca
2+ from intracellular ER stores (11, 12). In microglia, 
UDP-preferring P2Y6R and ADP-preferring P2Y12R have prominent roles in calcium signalling, 
which mediates microglial activation and is heavily dependent on store-operated Ca2+ entry 
(SOCE) (20-22). P2Y12 receptors are also expressed by oligodendrocytes/myelin and have 
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unresolved roles in demyelination (23-25). In the case of P2XR,  heteromeric P2X1/P2X5R 
mediate fast physiological signalling in astrocytes (26, 27), although this is not a universal 
feature of astrocytes (28), and it is not clear that P2XR mediate physiological signalling in 
oligodendrocytes or microglia under non-pathological resting conditions (10). Microglial 
P2X4R are activated by low micromolar ATP concentrations and are important in spinal 
microglia and their involvement in pain (29). The physiological role of P2XR in glia may be in 
doubt, but a universal feature is their expression of P2X7R, which are activated by high levels 
of ATP and mediate pathological responses in all three glial cell types - astrogliosis, 
microglial reactivity, and oligodendrocyte/myelin damage (19, 30-32). 
 
PURINE SIGNALLING IN GLIAL PATHOLOGY 
Multiple P2R are involved in the characteristic responses of glial cells to 
neuropathology (1). Microglia are central to immune and injury responses in the CNS and 
their activation state is carefully controlled by multiple ‘on’ and ‘off’ signals (33). ATP is an 
‘on’ signal and is released by astrocytes and by damaged cells following CNS injury to 
mediate microglial activation (34, 35). There is a prominent role for P2X7R in driving 
microglial activation and proliferation, and P2X7R play a major role in the microglial 
neuroinflammatory response (31, 36, 37). Reactive astrogliosis and glial scar formation is a 
more protracted process and involves prominent roles for both P2X7 and P2Y1R subtypes (9). 
In addition, ATP stimulates the production of pathological levels of pro-inflammatory 
cytokines and prostaglandin E2 (PGE2) by astrocytes, resulting in a double hit and increased 
neuroinflammation and damage (38). The actions of ATP on astroglial and microglial 
purinoceptors results in a vicious cycle in which P2Y1R on reactive astrocytes stimulate 
production of several cytokines/chemokines that activate microglia (39, 40), and P2X7R on 
 6 
activated microglia stimulate secretion of multiple cytokines, including IL-6, TNF-α, and IL-
1, which are key mediators of neurodegeneration, inflammation and pain (41, 42). The 
earliest response of microglia to injury is the rapid ATP-mediated extension of their 
processes to the area of damage and to seal it off from further damage (34, 43). ATP-
induced microglial chemoattraction is principally mediated by P2X4R and P2Y12R (44). P2Y12R 
are expressed by resting microglia and mediate their immediate chemotactic response to 
injury (22), whereas P2X4R are expressed mainly in activated microglia (45) and control their 
fate and survival (46). P2X4R in activated microglia are also central to neuropathic pain (29, 
47, 48). Nerve injury induces increased expression of P2X4R in spinal cord microglia, and 
their activation by ATP triggers calcium influx and the release of brain-derived neurotrophic 
factor (BDNF), which in turn induces neuronal hyperexcitability (49, 50). P2Y6R are also 
upregulated in activated microglia and specifically promote a phagocytic phenotype in 
response to UDP leaked from damaged cells (21, 51). Activation of P2Y6R can reduce the 
permeability of P2X4R, suggesting the interplay between UDP- and ATP-activated receptors 
are important in regulating microglial responses to injury (52). 
 
P2X7R are central to white matter pathology and ATP-mediated loss of 
oligodendrocytes/myelin (53). Oligodendrocytes constitutively express P2X7R and their 
blockade protects against demyelination in experimental autoimmune encephalomyelitis 
(EAE), a model of multiple sclerosis (MS) (54), degeneration following neurotrauma (55), and 
oligodendrocyte loss in ischemia (19). Oligodendrocytes are highly susceptible to 
ischemia/hypoxia and enhanced ATP signaling during oxygen-glucose deprivation (OGD) 
activates oligodendroglial P2X7R and cytosolic Ca
2+ overload, resulting in cell death (19). 
Similarly, the cytotoxic effects of P2X7R in OGD have been demonstrated in microglia (56).  
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In contrast, P2Y1R are protective against ischemic damage in astrocytes and treatment with 
2-MeSADP reduces cytotoxic edema and brain infarction in mice (57-59). However, over-
activation of P2Y1R induces astrocyte reactivity, indicating the ‘Jeckyll and Hyde’ nature of 
purine signalling (9). Oligodendrocytes and their progenitors (OPs) also express P2Y1R (6, 11, 
12, 60-62), and both P2Y1R and P2X7R in OPs are likely to be involved in oligodendrocyte 
regeneration and remyelination, which are prominent features of neuropathology (63-65). 
ATP and its breakdown product adenosine regulate the migration, proliferation and 
differentiation of OPs, acting via A1R, P2Y1R and P2X7R receptors (60, 66, 67). Moreover, 
ATP acting on astroglial P2R triggers their release of leukemia inhibitory factor (LIF) which 
promotes myelination (68). P2Y12R are also enriched in oligodendrocytes/myelin and are 
present in demyelinated lesions, but their precise functions in myelination/demyelination 
are unresolved (23-25). 
 
PURINOCEPTOR SIGNALLING IN THE AGEING BRAIN 
There is a loss of glial function in the ageing brain and glial cells are affected at early 
stages of neurodegenerative processes in Alzheimer’s disease (AD) (69). P2X1/5R-mediated 
calcium signalling in astrocytes was decreased in ageing (27, 70), and there is evidence in 
mouse models of AD of enhanced calcium signalling in astrocytes associated with P2Y1R-
mediated release of ATP from reactive astrocytes (71). Dysregulation of calcium 
homeostasis is a central thesis in AD (72), and increased astroglial calcium signalling is 
observed in animal models of AD and on exposure of astrocytes to β-amyloid (A) (73). Aβ 
increases the amount of ATP released from the astrocytes (74), which would have diverse 
effects on glial cells in AD. Aged microglia express higher levels of P2Y12R and respond to 
extracellular ATP by becoming less dynamic and ramified, opposite to the response of young 
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microglia (75). These studies are consistent with evidence of microglial senescence and 
increased inflammation in the ageing brain (76, 77). In addition, there is up-regulation of 
P2X₇R and increased levels of IL-6, TNF-α, and IL-1 in ageing microglia (78, 79). A vicious 
cycle of increased P2Y1R-mediated release of ATP from astrocytes and increased expression 
of microglial P2X7R would enhance production of cytokines in microglia. 
 
SUMMARY AND CONCLUSIONS 
Purine receptors are central to glial signalling and mediate bipartite effects in glial 
physiology and pathology, and a common theme is that P2X7R and P2Y1R mediate damage 
and repair, respectively. Astrocytes release ATP to act on microglia and oligodendrocytes to 
integrate them within a glial network. In pathology, ATP released from astrocytes and 
damaged cells mediates astrocyte reactivity, microglial activation and 
oligodendrocyte/myelin loss. Moreover, purinergic signalling is likely to play an important 
role in glial dysfunction in the ageing brain and AD, with consequent effects on 
neurodegeneration. Hence glial purine receptors are emerging as drug targets and blockade 
of P2X7R reduces pathology and improves outcome in mouse models of stroke, MS, AD and 
hyperalgesia (54, 80-82). Furthermore, P2X7R drive microglial activation and increase 
production of pro-inflammatory cytokines TNF-α, IL-6, and IL-1, which are key mediators of 
neurodegeneration and oligodendrocyte/myelin damage. In addition, activated microglia 
express P2Y13R and P2Y14R (83-85) and P2Y6R specifically promote a phagocytic microglial 
phenotype, whereas P2Y12R are associated with demyelinating lesions. Overall, purinergic 
receptors are potentially key drug targets for modulating astrocytes and microglia and, 
either directly or indirectly, providing cytoprotection for oligodendrocytes. However, 
purinergic signalling has a ‘Jekyll and Hyde’ nature that is mimicked by glial pathology, 
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whereby they mediate both tissue destruction and repair. It may not be a simple matter of 
blocking glial P2R in human neuropathology, since this could result in increased 
neurodestruction. 
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